Patents by Inventor Wenyu Zhu

Wenyu Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoline compounds as inhibitors of KRAS
    Patent number: 11939328
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: March 26, 2024
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Matthew McCammant, Artem Shvartsbart, Wenyu Zhu, Bin Hu, Chao Qi, Xiaozhao Wang, Wenqing Yao, Alexander Sokolsky
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 11851442
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: December 26, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
    Publication number: 20230226040
    Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
    Type: Application
    Filed: November 21, 2022
    Publication date: July 20, 2023
    Inventors: Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
  • SPIRO COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230192696
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Le ZHAO, Xiaozhao WANG, Wenyu ZHU, Haolin YIN, Liangxing WU, Wenqing YAO
  • HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230151005
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 18, 2023
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
  • PYRAZOLOQUINOLINE KRAS INHIBITORS
    Publication number: 20230143938
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 11, 2023
    Inventors: Wenyu ZHU, Xiaozhao WANG, Wenqing YAO
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230144051
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 11, 2023
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20230121440
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: July 18, 2022
    Publication date: April 20, 2023
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • Spiro compounds as inhibitors of KRAS
    Patent number: 11530218
    Abstract: Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: December 20, 2022
    Assignee: INCYTE CORPORATION
    Inventors: Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
  • 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
    Publication number: 20220331296
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: November 16, 2021
    Publication date: October 20, 2022
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES
    Publication number: 20220233529
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 29, 2021
    Publication date: July 28, 2022
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220213090
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 24, 2021
    Publication date: July 7, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220194931
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 23, 2022
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20220135570
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 11207302
    Abstract: The present invention is directed to 1, 2, 5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2, 3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1, 2, 5-oxadiazole derivatives.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: December 28, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20210387998
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 16, 2021
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • FUSED TRICYCLIC KRAS INHIBITORS
    Publication number: 20210355121
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 18, 2021
    Inventors: Wenyu ZHU, Xiaozhao WANG, Artem SHVARTSBART, Chao Qi, Rocco Policarpo, Wenqing Yao
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 11161855
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 2, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Fused pyrazine derivatives as A2A / A2B inhibitors
    Patent number: 11161850
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 2, 2021
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu
  • Food processor
    Patent number: D1017315
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: March 12, 2024
    Inventors: Zechun Zhu, Wenqian Xu, Wenyu Yan